News & Events
April 17, 2007 discovery biosciences announces its involvement with BioSyndicate, a new portal focused on helping you find just the right life-science industry specialists for your consulting or contracting needs.
October 1, 2002 discovery biosciences announces partnership with Tooned In, Inc. to provide graphic services.
June 1, 2002 discovery biosciences announces partnership with Pivotalinfo to provide IP and market research services.
The Next Disruptive Technology - Bio-informatics: The Convergence of Info Tech and Bio Tech.
May 20-22, 2001 5th International Biotech & Infotech Summit
April 17, 2007 discovery biosciences announces its involvement with BioSyndicate
discovery biosciences announces its involvement with BioSyndicate. BioSyndicate is a new alliance of life-science specialists offering consulting and/or contracting services The BioSyndicate portal will help potential clients and service providers find each other. The range of expertise represented will broadly reflect industry needs, such as bio/chemoinfomatics services, marketing and marketing analysis, strategic planning, technology/IP assessment and development, media preparation, etc.. Details will be coming soon. However, if you provide independent services to our industry and are interested in finding learning more about becoming a member, please contact us.
March 20, 2007 You are cordially invited to join Microsoft, industry experts and your peers as Microsoft presents BioIT Forum, April 19, 2007 in Mountain View CA.
We have put together an intriguing agenda featuring our special guest, Dr. Tim Hunkapiller, presenting The $1,000 Genome What Will It Mean, What Will It Take, and When Will it Happen?. Dr. Hunkapiller has been a pioneering presence in computational biotechnology since its infancy 30 years ago and is co-inventor of the largest selling analytical research instrument in the world: the Perkin Elmer/Applied Biosystems DNA sequencer.
We will also present a number of Microsoft technologies that are directly relevant to Life Science discovery and development. This event is an opportunity to understand how the current generation of Microsoft technology can accelerate the discovery process. Seating is limited so please register early to guarantee your place.
May 1, 2006 discovery biosciences joins the BioIT Alliance.
discovery biosciences announces it's joining Microsoft's BioIT Alliance. The Alliance is a group of organizations working together to realize the potential of personalized medicine. The Alliance unites the pharmaceutical, biotech, hardware, and software industries to explore new ways to share complex biomedical data and collaborate among multi-disciplinary teams to speed the pace of discovery in the life sciences. Members are particularly interested in the development capabilities of Microsoft platforms such as Office and Sharepoint. full story...
November, 2003 discovery biosciences announces discoverySource
discovery biosciences announces discoverySource, a suite of technology source materials available in text and SQL-ready formats. These will be primarily text-based corpora that can be searched and mined directly with many commercial tools, including our own discoveryView text mining system. Our first release is the complete text source of US patents since 1976 in the least expensive, cleanest and most easily accessible format available anywhere - even the patent office. Up until now, these data have been available through the US Patent Office in a hodgepodge of tape and disk formats depending on the years included. Most patent search companies no longer provide external copies, requiring expensive on-line service charges. This makes it nearly impossible to develop and validate new mining algorithms on these critical data. We have now taken these data and provide a common, readable format ready for import into an SQL-based system or used as flat text delivered on a single Firewire and/or USB2.0 hard disk drive, readable on essentially any computer by just plugging it in. We have also "cleaned" the data to better insure consistency in dates and references. Updates will be available as well. We deliver this resource at a fraction of the cost that one would pay the USPTO for just the raw text (and un-cleaned) on multiple tapes (DLT) and DVDs. We use this same resource in our discoveryView text mining system and are making it available here for those with their own interests and needs in large text corpora or the patent database in particular. We will be adding new source materials in the near future. Please email or call us for pricing and delivery schedules. full story...
discovery biosciences and Tooned In Inc.announce a partnership to provide animated graphics for life science researchers and organizations. Tooned In is an animation company in Seattle, WA expert in traditional 2D techniques as well as computer-aided 3D modeling and animation and web-friendly delivery methods such as Flash. They develop a wide range of entertainment and gaming graphics as well as technical materials. Combining this expertise with the technical and scientific insight of discovery biosciences will allow us to provide technically accurate, visually engaging and effective illustration of scientific and technical ideas as well as marketing, training and educational materials. The style of illustration can range from cartoony all the way to realistic. We can provide affordable solutions for the single researcher needing to illustrate a novel scientific discovery or an entire marketing and educational portfolio for a life science company. full story...
discovery biosciences announces a partnership with Pivotalinfo, LLC to provide IP and market research services. Pivotalinfo is a Washington-based company specializing in intellectual property prior art research as well as market intelligence gathering. Their clients include multiple Fortune 500 corporations and independent researchers and authors. Combining their expertise and knowledge of search techniques and intelligence data sources with discovery biosciences' experience and knowledge of life science technologies, chemistry, biology and computational science will provide a powerful new resource for any researcher or organization that needs to know what is known in their domain of interest. full story...
October 1, 2001 discovery biosciences announces the release of jot 3.0
discovery biosciences announces the release of jot 3.0. jot is the first commercially supported dot matrix viewer capable of supporting whole genome comparisons. It incorporates many unique scaling and graphic tools as well as acceleration by the Paracel Genematcher. With Version 3.0, jot now supports the use of Blast for those with no Genematcher resource. This greatly increases the accessibility of jot. Blast can be directly launched from jot, or results from other Blast servers can be imported. Version 3.0 also includes several improvements to 2.0. A demonstration version of jot can be downloaded for free. full story...
The Next Disruptive Technology -
Bio-informatics: The Convergence of Info Tech and Bio Tech
Location : Bellevue Hyatt Regency, 900 Bellevue Way NE
As industry giants like IBM and Compaq pour $100
million each into research projects on biotechnology, many questions are raised.
What are the practical applications? How will it improve our quality of life?
What does the hybrid of information technology and biotechnology called
bioinformatics mean for our economy, for the Pacific Northwest and for you
On September 19th, the MIT Enterprise Forum and the Washington Biotechnology and Biomedical Association will assemble a panel of experts to offer pivotal perspectives on this fast-emerging field. Panelists include:
Bruce Carter, President and CEO, Zymogenetics
Jeff Augen, Director - Business Strategy Life Sciences, Blue Gene, IBM
Tim Hunkapiller, President and CSO, Discovery Biosciences
Steve Friend, President, Rosetta Inpharmatics
Robert T. Nelsen, Managing DIrector, Arch Venture Partners
Patrick O'Hara, VP Bioinfomratics, Zymogenetics
Late last June, Bio/Pharma industry leaders
George Poste, Leroy Hood, David Kingsbury, Ed Penhoet, Carl Feldbaum and
a couple hundred other executives got together for a "little"
announcement -- the completion of the mapping of the Human Genome. The
announcement was but one note at the 4th International Biotech & Infotech
Summit as the attendees were all deeply engaged in discussing subjects that will
generate future historic milestones...
Wonder what they will be discussing May 20-22, 2001 at UCSF's Laurel Heights Campus? Perhaps you should register right now... after all, "Biotech Evolutions" move very quickly -- and so should you. Topics and confirmed participants include:
TAMING THE TORRENT OF GENOMIC DATA: How Computer Science and Math are Shaping a "New Biology"
David Kingsbury, Ph.D., Chairman of the Board & Chief Executive Officer, Discovery Biosciences Corporation
Peter J. Farley, M.D., President & Chief Executive Officer, BeoWulf
David Haussler, Ph.D., Associate Director, California Institute for Bioengineering, Biotechnology & Quantitative Biomedical Research
Russ B. Altman, M.D., Ph.D. , Director, Biomedical Infomatics Training Program Associate Professor of Medicine, Stanford University
BIOTECH'S NEXT GREAT ACT: Making a Business of Proteomics
Tim Hunkapiller, Ph.D., Co-founder, President & Chief Scientific Officer, Discovery Biosciences
Donald Kennedy, Ph.D., Panel Chairman, Editor-in-Chief, Science Magazine
Rudi Aebersold, Ph.D., Professor & Co-founder, Institute for Systems Biology
Raj Parekh, Ph.D., Chief Scientific Officer, Oxford GlycoSciences
Lawrence K. Cohen, Ph.D., Chief Executive Officer, Zyomyx
Check the agenda and register --> http://www.biotechsummit.com. This year's sponsors include: The Nasdaq Stock Market; Science Magazine; Alloy Ventures with: Sofinnova Ventures; Techno Venture Management and Earlybird Ventures; California Healthcare Institute, and BIO.
Discovery 2001: Innovative Advances in Drug Discovery
March 26-29th , 2001 in San Diego, CA.
by International Institute of Research.
How IT Can Enable Cutting Edge Drug Discovery
Worldwide Pharmaceutical Industry Manager, Microsoft Corp.
President and Chief Scientific Officer Discovery Biosciences Corporation
Information technology is being incorporated into the drug discovery process by many healthcare organizations. This session explores a joint alliance between Microsoft and one of their lead discovery partners. A successful business model has been developed by Microsoft which has been incorporated into their collaboration process. Discussed are elements of information technology that can facilitate drug discovery and maximizes the outcome benefits.
February 20, 2001 discovery biosciences announces the release of jot 2.0
discovery biosciences announces the release of jot 2.0. jot is the first commercially supported dot matrix viewer capable of supporting whole genome comparisons. It incorporates many unique scaling and graphic tools as well as acceleration by the Paracel Genematcher. It has recently been employed to cross compare all human chromosomes from the Celera genome project.. Version 2.0 includes several improvements to 1.0, including: support for multiple, pooled comparisons, export of graphics files, more sophisticated trace analysis, more refined filtering capabilities, stronger annotation support and graphics and more flexible scaling options. A demonstration version of jot can be downloaded for free.
January 10, 2001 discovery biosciences announces release of multiFPC 1.2
discovery biosciences announces the release of multiFPC 1.2. multiFPC 1.2 is the first generally available tool for large-scale clone mapping using four-color fluorescent data from automated sequencers. Although based on the FPC program from the Sanger Institute, multiFPC 1.2 represents a significant advance in both ease of analysis and statistical robustness. It also greatly facilitates the design of large-scale mapping operations. Version 1.2 now includes support for single-base extension labeling in four or more colors. The current version is free for download. Fully supported commercial versions are available. full story...
Copyright © Discovery Biosciences Corporation, 2007